Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
To develop the new treatment for hypertension, that improves medical adherence, I focused on the vaccine strategy. To avoid the injection-related pain and skin adverse events, I aimed to create a new non-injectable anti-hypertensive vaccine. For the development of oral anti-hypertensive vaccine, the expression vector which angiotensin II type 1 receptor (AT1) - Cholera toxin B subunit(CTB) chimeric sequence was inserted into was used to transformed the rice. Although resultant transgenic rice seeds expressed AT1-CTB protein, its immunogenicity to AT1 was poor. For the development of nasal vaccine, AT1 partial peptide was synthesized and conjugated with pneumococcal surface protein A (PspA). AT1-PspA antigen was mixed with adjuvant and incorprated into nanogels. Intranasal immunization with AT1-PspA vaccine induced AT1-specific serum IgG antibody and also lower blood pressure in the spountaneously hypertensive rats.
|